DrugAlert provides timely advice direct to your inbox and is based on information from drug manufacturers regarding critical changes to medication access such as the discontinuation, short supply or unavailability, recalls and other important drug-related information. See below to view the most recent volumes of DrugAlert.
Further to DrugAlert vol 875, HPS Pharmacies wish to advise that Pfizer is continuing to experience a supply interruption for Heparin as follows: Heparin Sodium Heparin sodium 5000IU/5mL ARTG 49232 The supply interruption for…
Read more
HPS Pharmacies wish to advise that Boehringer Ingelheim intends to discontinue Metalyse® 40mg as follows: Metalyse® Powder for Injection Tenecteplase (rch) 40mg ARTG 75012 The 40mg presentation of Metalyse® will be deleted in September…
Read more
HPS Pharmacies wish to advise that multiple suppliers are experiencing a supply interruption for gliclazide tablets, as follows. Product ARTG Current Status APX-Gliclazide 80mg 337479 Late March 2024 Nidem 80mg 79023 Early March 2024…
Read more
Further to DrugAlert volume 890, HPS Pharmacies wishes to provide an update on the availability of morphine oral solution. While Ordine® Oral Solution was discontinued by Mundipharma in 2023, Arrotex Pharmaceuticals has now announced…
Read more
HPS Pharmacies wish to give notice that Seqirus, in consultation with the Therapeutic Goods Administration (TGA), has issued a product defect correction for ADT™ Booster as follows: ADT™ Booster Diphtheria and Tetanus Vaccine ARTG…
Read more
Further to DrugAlert vol 902, HPS Pharmacies wish to give notice that Aspen Pharmacare Australia is experiencing a supply interruption for the following local anaesthetic products: Product ARTG Anticipated availability Xylocaine 2% Adrenaline 1:200,000…
Read more
